Skip to main content
Premium Trial:

Request an Annual Quote

MDI, Launch Diagnostics Distributing MRSA Test

a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Molecular Detection and Launch Diagnostics today announced an exclusive distribution agreement for MDI's real-time PCR-based diagnostic for methicillin-resistant Staphylococcus aureus.

The agreement covers the UK, France, and Republic of Ireland. Other terms of the agreement were not disclosed.

The two firms also announced that the test, called Detect-Ready MRSA, has been launched in the UK and the Republic of Ireland.

Detect-Ready MRSA is a qualitative RT-PCR in vitro diagnostic test for detecting MRSA nasal colonization and is used to help prevent bacterial infection in hospitals and other healthcare settings.

Based in Wayne, Pa., MDI develops molecular diagnostic tests. Launch Diagnostics, headquartered in Longfield, UK, is a distributor of reagents, instruments, and related consumables.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.